Nuveen
KLRS icon

Nuveen’s Kalaris Therapeutics KLRS Stock Holding History

Nuveen’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13.5K Buy
+4,639
New +$17.9K ﹤0.01% 4480
2023
Q4 		– Sell
-7,092
Closed -$351K – 3368
2023
Q3 		$351K Sell
7,092
-46
-0.6% -$3.14K ﹤0.01% 2941
2023
Q2 		$558K Buy
7,138
+601
+9% +$57.1K ﹤0.01% 2888
2023
Q1 		$592K Sell
6,537
-505
-7% -$64.3K ﹤0.01% 2766
2022
Q4 		$831K Sell
7,042
-638
-8% -$108K ﹤0.01% 2754
2022
Q3 		$1.39M Sell
7,680
-62
-0.8% -$9.7K ﹤0.01% 2577
2022
Q2 		$694K Buy
7,742
+4,228
+120% +$443K ﹤0.01% 2933
2022
Q1 		$613K Buy
3,514
+26
+0.7% +$5.19K ﹤0.01% 2955
2021
Q4 		$1.15M Sell
3,488
-286
-8% -$133K ﹤0.01% 2813
2021
Q3 		$2.08M Sell
3,774
-83
-2% -$38.4K ﹤0.01% 2657
2021
Q2 		$1.75M Sell
3,857
-479
-11% -$247K ﹤0.01% 2775
2021
Q1 		$2.33M Buy
4,336
+883
+26% +$742K ﹤0.01% 2544
2020
Q4 		$3.05M Buy
3,453
+171
+5% +$132K ﹤0.01% 2298
2020
Q3 		$2.08M Buy
+3,282
New +$2.24M ﹤0.01% 2365

Other funds holding KLRS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Belpointe Asset Management
Belpointe Asset Management Reno, Nevada $3.63B AUM 17.81% 1-Year Est. Return
Fortis Capital Advisors
Fortis Capital Advisors Prairie Village, Kansas $1.3B AUM 27.43% 1-Year Est. Return
WealthTrust Asset Management
WealthTrust Asset Management Destin, Florida $181M AUM 17.81% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return
Strengthening Families & Communities LLC
Strengthening Families & Communities LLC Boston, Massachusetts $459M AUM 29.64% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Nuveen's KLRS Position: Q3 2026 in Review

Nuveen opened a new position in Kalaris Therapeutics (KLRS) in Q3 2026: 4,639 shares worth $13.5K. The stake represents ﹤0.01% of the portfolio and ranks #4480 among its holdings. This is a return to the name: Nuveen previously reported a position in KLRS as recently as Q3 2023.

Nuveen first reported a position in KLRS in Q3 2020 and has held it in 14 quarters since. The position peaked at $3.05M in Q4 2020. 14 funds tracked by Wall St. Rank hold KLRS as of Q3 2026.

  • Nuveen held 4,639 shares of Kalaris Therapeutics worth $13.5K as of Q3 2026.
  • Kalaris Therapeutics was a new Nuveen position in Q3 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #4480 holding.
  • Nuveen first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 14 quarters since.
  • Nuveen's Kalaris Therapeutics position peaked at $3.05M in Q4 2020.
  • 14 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.